PCM
SGMO

Penserra Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Penserra Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-87,000
Closed -$52K – 1350
2023
Q3 		$52K Sell
87,000
-12,352
-12% -$13.2K ﹤0.01% 991
2023
Q2 		$129K Buy
99,352
+61,642
+163% +$84.2K ﹤0.01% 898
2023
Q1 		$66K Buy
37,710
+2,090
+6% +$5.96K ﹤0.01% 821
2022
Q4 		$111K Sell
35,620
-8,257
-19% -$32K ﹤0.01% 792
2022
Q3 		$214K Buy
43,877
+31,829
+264% +$164K 0.01% 627
2022
Q2 		$49K Buy
12,048
+672
+6% +$2.91K ﹤0.01% 911
2022
Q1 		$66K Buy
+11,376
New +$67.6K ﹤0.01% 940
2021
Q4 		– Sell
-3,325
Closed -$29K – 1529
2021
Q3 		$29K Buy
3,325
+50
+2% +$494 ﹤0.01% 1191
2021
Q2 		$39K Buy
3,275
+20
+0.6% +$226 ﹤0.01% 1055
2021
Q1 		$40K Sell
3,255
-15
-0.5% -$202 ﹤0.01% 851
2020
Q4 		$51K Buy
3,270
+2,066
+172% +$24.2K ﹤0.01% 683
2020
Q3 		$11K Buy
+1,204
New +$13K ﹤0.01% 808

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Penserra Capital Management's SGMO Position: Q4 2023 in Review

Penserra Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2023, closing a stake of 87,000 shares — an estimated $52K sold.

Penserra Capital Management first reported a position in SGMO in Q3 2020 and held it in 12 quarters. The position peaked at $214K in Q3 2022. 130 funds tracked by Wall St. Rank hold SGMO as of Q4 2023.

  • Penserra Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2023 after selling out during the quarter.
  • Penserra Capital Management sold 87,000 SANGAMO THERAPEUTICS INC shares in Q4 2023, an estimated $52K.
  • Penserra Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2020 and held it in 12 quarters.
  • Penserra Capital Management's SANGAMO THERAPEUTICS INC position peaked at $214K in Q3 2022.
  • 130 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2023.

Based on Penserra Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.